Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.59 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.59 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924436 | 0.89 | KMT2A (0.54) | ALDH1A1HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL27842881 | 0.85 | ALDH1A1 (0.60) | ALDH1A1HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14454210 | 0.85 | ALDH1A1 (0.47) | ALDH1A1HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL28797466 | 0.84 | ALDH1A1 (0.59) | ALDH1A1HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL14872772 | 0.83 | TAS1R3 (0.54) | ALDH1A1HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2542357 | 0.83 | TAS1R3 (0.68) | ALDH1A1TAS1R3TAS1R1TAS1R2RAB9A | |
| SCHEMBL104388 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL178430 | 0.81 | TAS1R3 (0.66) | HPGDTAS1R3TAS1R1TAS1R2RAB9A | |
| SCHEMBL4066954 | 0.80 | TAS1R3 (0.88) | ALDH1A1HPGDTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13294935 | 0.79 | HDAC7 (0.53) | ALDH1A1HPGDRAB9ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7947834-B2 | Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-7947834-B2 | Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | ALDH1A1 3128/4885HPGD 4110/4885TAS1R3 1218/4885 |
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | HSD11B1, HSD3B1, ADH1C | ALDH1A1 46/4885HPGD 26/4885TAS1R3 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.